MHRA’s new International Recognition Procedure: how does it shape up?


12 September 2023 - The field of life sciences and medicine development has become increasingly global. Multinational firms must make informed and often challenging decisions about where and when to locate their activity. 

National regulatory frameworks are a key consideration when these decisions are made in boardrooms. It is therefore vital for regulators to provide a globally competitive approval system that is both proportionate and committed to ensuring patient safety, while also being attractive to inward investment and industry research and development.

Read ABPI press release

Michael Wonder

Posted by:

Michael Wonder